| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6957040cd6075e8cdf2616604541e93f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 |
| filingDate |
2019-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50fd4c3bbca321bb8c70d87547355803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6125ea8474dda8f70283d29044264992
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41d918ad51d1c4d1a1b4e39a557bc40d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c7dcd49fe4969a392b9f6938a421c10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eef012146cfa43dd4c25232d5629b5a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db6bd01b01f02564f4041c2d787f4847
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed21994197f944224e4a587973a6f000
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dccbfba51e423fdd157a923810b77a23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c0f7230e0900aab3df34ac3dc7bc238
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49c99104089b8ebb1be12a8a2b9d4a2e |
| publicationDate |
2021-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021128544-A1 |
| titleOfInvention |
Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent |
| abstract |
The invention relates to an aqueous ophthalmic pharmaceutical composition comprising:n a) at least 0.4% w/v of bilastine, of formula nn n n n n n n n n n n n or a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine salt or solvate thereof is completely dissolved in the pharmaceutical composition; n b) at least one β-cyclodextrin; and n c) at least one pharmaceutically acceptable water-soluble gelling agent; and wherein the pH is comprised between 4 and 9. n and its use in the treatment and/or prevention of conditions mediated by H 1 histamine receptor, such as allergic disorders or diseases. The invention relates to the treatment and/or prevention of allergic conjunctivitis. |
| priorityDate |
2018-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |